Notice of Results

London, UK, 25 April 2017: BTG plc (LSE: BTG), the global specialist healthcare company, will announce its preliminary results for the twelve months ended 31 March 2017 on Tuesday 16 May 2017.

For further information, please contact:

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

FTI Consulting

Ben Atwell / Simon Conway

+44 (0)20 3727 1000

About BTG

BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.